Ovarian cancer associated with the BRCA1/BRCA2 mutations usually occurs about ten years earlier (usually in the fourth decade of a woman’s life) and is characterized by a substantially higher clinical stage compared with the general population (stage III and IV disease according to the International Federation of Gynecology and Obstetrics (FIGO) classification system) [13]. This evidence concerns the gene BRCA1 and ovarian carcinoma.